Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
西雅圖，2025年1月2日（環球新聞）——Adaptive Biotechnologies Corporation（納斯達克：ADPT），一家商業階段的生物技術公司，旨在將適應性免疫系統的遺傳學轉化爲臨牀產品，以便診斷和治療疾病，今天宣佈將參加在加利福尼亞州舊金山舉行的第43屆年度J.P.摩根醫療保健大會。
Adaptive Biotechnologies' management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: .
Adaptive Biotechnologies的管理層定於1月14日（星期二）太平洋時間下午5:15 / 東部時間晚上8:15進行介紹。感興趣的各方可以在公司網站的「投資者」部分訪問該介紹的實時和存檔網絡廣播：。
About Adaptive Biotechnologies
關於Adaptive Biotechnologies
Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Adaptive Biotechnologies（「我們」或「我們的」）是一家商業階段的生物技術公司，專注於利用適應性免疫系統的固有生物學來變革疾病的診斷和治療。我們認爲，適應性免疫系統是自然界最精密的診斷和治療方法，但無法解碼使醫療界無法充分發揮其能力。我們的專有免疫醫藥平台以規模、精度和速度揭示並翻譯適應性免疫系統的巨大遺傳信息。我們將我們的平台應用於與生物製藥公司合作，爲藥物開發提供信息，並在兩個業務領域：最小殘留疾病（MRD）和免疫醫學中開發臨牀診斷。我們的商業產品和臨牀管線使我們能夠診斷、監測和治療癌症、自身免疫疾病和傳染病等疾病。我們的目標是開發和商業化針對每位患者量身定製的免疫驅動的臨牀產品。
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
適應性投資者
卡里娜·卡爾薩迪拉，副總裁，投資者關係
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
適應性媒體
企業傳媒副總裁Erica Jones
206-279-2423
media@adaptivebiotech.com
譯文內容由第三人軟體翻譯。
